Cytek Biosciences, Inc. (CTKB) total liabilities
Cytek Biosciences, Inc. (CTKB) had total liabilities of $119.80M at the end of fiscal 2025 (December 31, 2025). That is 15.5% higher than the $103.76M of fiscal 2024. Figures as of 18 Nov 2026, 18:17 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Total liabilities, fiscal 2025
- $119.80M
- Change on fiscal 2024
- +15.5%
- Growth, 5 years
- +23.5% a year
- Highest on record
- $119.80Mfiscal 2025
- Lowest on record
- $41.69Mfiscal 2020
- Fiscal years on record
- 62020–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.
Cytek Biosciences, Inc. total liabilities, in more detail
Over the five fiscal years to 2025 total liabilities grew at a compound 23.5% a year. Across the 6 fiscal years on record (2020–2025), the highest was $119.80M in fiscal 2025 and the lowest $41.69M in fiscal 2020.
Total liabilities by fiscal year
Cytek Biosciences, Inc. total liabilities, year by year
| Fiscal year | Total liabilities | Change | Year ended |
|---|---|---|---|
| 2025 | $119.80M | 15.5% up | |
| 2024 | $103.76M | 2.3% up | |
| 2023 | $101.39M | 7.9% up | |
| 2022 | $93.93M | 62.2% up | |
| 2021 | $57.92M | 38.9% up | |
| 2020 | $41.69M | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest.
How to read it
It is broader than debt: read it against total assets, and remember that for a bank or an insurer customer deposits and policy reserves are liabilities too.
Cytek Biosciences, Inc., figure by figure
- Cytek Biosciences, Inc. market cap
- Cytek Biosciences, Inc. revenue
- Cytek Biosciences, Inc. earnings
- Cytek Biosciences, Inc. earnings per share (EPS)
- Cytek Biosciences, Inc. P/E ratio
- Cytek Biosciences, Inc. P/S ratio
- Cytek Biosciences, Inc. P/B ratio
- Cytek Biosciences, Inc. free cash flow
- Cytek Biosciences, Inc. operating margin
- Cytek Biosciences, Inc. dividend
- Cytek Biosciences, Inc. shares outstanding
- Cytek Biosciences, Inc. total debt
- Cytek Biosciences, Inc. cash on hand
- Cytek Biosciences, Inc. total assets
- Cytek Biosciences, Inc. net assets (shareholders' equity)
- Cytek Biosciences, Inc. return on equity (ROE)
- Cytek Biosciences, Inc. return on invested capital (ROIC)
Cytek Biosciences, Inc. (CTKB) overview: price, valuation and scorecard
Cytek Biosciences, Inc. total liabilities: questions and answers
How large are Cytek Biosciences, Inc.'s total liabilities?
Cytek Biosciences, Inc. (CTKB) had total liabilities of $119.80M at the end of fiscal 2025 (December 31, 2025). That is 15.5% higher than the $103.76M of fiscal 2024.
What is the growth rate of Cytek Biosciences, Inc.'s total liabilities?
Over the five fiscal years to 2025 total liabilities grew at a compound 23.5% a year.
What are the highest and lowest total liabilities figures on record for Cytek Biosciences, Inc.?
Across the 6 fiscal years on record (2020–2025), the highest was $119.80M in fiscal 2025 and the lowest $41.69M in fiscal 2020.
How is Cytek Biosciences, Inc.'s total liabilities calculated?
Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest. For Cytek Biosciences, Inc. it is on record here for 6 fiscal years, 2020 to 2025.
Fiscal years are named for the calendar year they end in.
Learn: total liabilities
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Cytek Biosciences, Inc. (CTKB) total liabilities”, data as of 18 November 2026. https://funkfolio.com/stock/CTKB/total-liabilities
Underlying data: the company's filings with the SEC and Yahoo Finance.